Press Releases :: Nighthawk Biosciences, Inc. (SCPX)

Nov 14, 2014 7:30am EST

Heat Biologics, Inc. Reports 2014 Third Quarter Financial Results

Oct 27, 2014 8:05am EDT

Heat Biologics, Inc. Commences Patient Dosing of Phase 2 Clinical Study of Vesigenurtacel-L for the Treatment of Bladder Cancer

Oct 02, 2014 7:35am EDT

Heat Biologics, Inc. Completes Enrollment of Phase 1 Clinical Trial of Vesigenurtacel-L for the Treatment of Bladder Cancer Required to Advance to Phase 2

Sep 30, 2014 7:30am EDT

Heat Biologics, Inc. to Present at the 13th Annual BIO Investor Forum in San Francisco on Tuesday, October 7, 2014

Sep 18, 2014 8:05am EDT

Heat Biologics Commences Patient Dosing in Phase 2 Study of Viagenpumatucel-L for the Treatment of Non-Small Cell Lung Cancer

Sep 04, 2014 7:30am EDT

Heat Biologics, Inc. to Present and Webcast at Two Investor Conferences in September

Aug 25, 2014 8:05am EDT

Heat Biologics, Inc. Closes on Up to $7.5 Million Secured Term Loan Facility

Aug 14, 2014 7:05am EDT

Heat Biologics, Inc. Reports 2014 Second Quarter Financial Results

Aug 04, 2014 8:05am EDT

Heat Biologics Amends Bladder Cancer Protocol for Early Advancement Into Phase 2 Clinical Studies

May 30, 2014 8:05am EDT

Heat Biologics Receives Green Light to Expand Enrollment of Its Phase 1/2 Study of HS-410 in Bladder Cancer Based on Encouraging Preliminary Safety Results

rss_feed News RSS